News
-
-
REGULATED PRESS RELEASE
bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid
bioMérieux receives U.S. FDA clearance for the new version of its molecular test, the BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid, targeting causes of gastroenteritis. The test detects 11 common bacteria, viruses, and parasites from one sample in about 1 hour, improving patient outcomes -
-
-
-
-
REGULATED PRESS RELEASE
bioMérieux strengthens its point of care presence with the acquisition of the immunoassay start-up SpinChip
bioMérieux strengthens its point of care presence with the acquisition of the immunoassay start-up SpinChip. The innovative diagnostics platform aims to revolutionize MI diagnosis and improve patient outcomes -
-
-
